Reneo Pharmaceuticals, Inc. (RPHM): Price and Financial Metrics
GET POWR RATINGS... FREE!
RPHM Stock Price Chart Interactive Chart >
RPHM Price/Volume Stats
| Current price | $2.71 | 52-week high | $6.46 |
| Prev. close | $2.70 | 52-week low | $1.79 |
| Day low | $2.45 | Volume | 78,421 |
| Day high | $2.79 | Avg. volume | 44,591 |
| 50-day MA | $2.33 | Dividend yield | N/A |
| 200-day MA | $2.74 | Market Cap | 66.48M |
Reneo Pharmaceuticals, Inc. (RPHM) Company Bio
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Latest RPHM News From Around the Web
Below are the latest news stories about RENEO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RPHM as an investment opportunity.
Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial ResultsIRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September 30, 2022. |
Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Third Quarter 2022 Financial ResultsIRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies … |
JMP Securities Initiates a Buy Rating on Reneo Pharmaceuticals (RPHM)E ratio…. |
Reneo Pharmaceuticals (RPHM) Investor Presentation - SlideshowThe following slide deck was published by Reneo Pharmaceuticals, Inc. |
RPHM Price Returns
| 1-mo | 16.31% |
| 3-mo | -15.84% |
| 6-mo | 0.37% |
| 1-year | -56.36% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 16.31% |
| 2022 | -72.75% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...